A vision for inclusive and transparent health data in the beyond. Learning
暂无分享,去创建一个
M. Tattersall | I. Judson | B. Seddon | C. McNeil | J. Morden | A. L. Pousa | L. Kilburn | Q. Campbell-Hewson | C. Benson | V. Bhadri | R. Cubedo | I. Hennig | A. Dangoor | C. Snowdon | Lisa Fox | S. Kernaghan | W. Joubert | J. M. Trufero | C. Toms | Katy Jarman | M. Leahy
[1] A. Rosenberg,et al. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. , 2019, The Lancet. Oncology.
[2] F. Du,et al. Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma , 2018, Clinical Cancer Research.
[3] J. Blay,et al. Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’ , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] I. Judson,et al. Activity of cediranib in alveolar soft part sarcoma (ASPS) confirmed by CASPS (cediranib in ASPS), an international, randomised phase II trial (C2130/A12118). , 2017 .
[5] S. Sleijfer,et al. Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials. , 2015, European journal of cancer.
[6] Krystal M. Straessler,et al. Modeling alveolar soft part sarcomagenesis in the mouse: a role for lactate in the tumor microenvironment. , 2014, Cancer cell.
[7] I. Judson,et al. Phase II Study of Cediranib in Patients with Advanced Gastrointestinal Stromal Tumors or Soft-Tissue Sarcoma , 2014, Clinical Cancer Research.
[8] S. Steinberg,et al. Cediranib for metastatic alveolar soft part sarcoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] M. Dewhirst,et al. Targeting the Lactate Transporter MCT1 in Endothelial Cells Inhibits Lactate-Induced HIF-1 Activation and Tumor Angiogenesis , 2012, PloS one.
[10] P. Casali,et al. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] J. Schellens,et al. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] E. Mayordomo,et al. Detection and characterization of EWSR1/ATF1 and EWSR1/CREB1 chimeric transcripts in clear cell sarcoma (melanoma of soft parts) , 2009, Modern Pathology.
[13] Huasheng Lu,et al. Hypoxia-inducible Factor 1 Activation by Aerobic Glycolysis Implicates the Warburg Effect in Carcinogenesis* , 2002, The Journal of Biological Chemistry.
[14] M. Ladanyi,et al. The precrystalline cytoplasmic granules of alveolar soft part sarcoma contain monocarboxylate transporter 1 and CD147. , 2002, The American journal of pathology.
[15] Alfons Meindl,et al. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25 , 2001, Oncogene.
[16] J. Blay,et al. Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. , 2018, The oncologist.
[17] Lars Holmgren,et al. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.
[18] M. Brennan,et al. Alveolar soft‐part sarcoma. A clinico‐pathologic study of half a century , 1989, Cancer.